NativePath Grass-Fed Collagen Peptides Review 2026 Explores Collagen Support for Women Comparing GLP-1 Wellness Routines

MIAMI, June 18, 2026 (Newswire.com) - Title Reference Notice: Phrases in this title - including "2.6% Hip Density Drop in 52 Weeks" and "What the Wegovy Label Discloses About Fractures" - refer to specific published research findings and FDA-reviewed prescribing information disclosures, each attributed in full within this article. "2.6% Hip Density Drop" refers to findings from Hansen et al. (eClinicalMedicine, 2024) in a specific study population with pre-existing reduced bone density using semaglutide 1.0 mg - not a universal finding for all GLP-1 users. "Wegovy Label" refers to the FDA-reviewed prescribing information for Wegovy; the fracture data cited is from the SELECT cardiovascular outcomes trial population. Readers should continue reading for full attribution and clinical context.

Disclaimers: This article is sponsored content about NativePath Grass-Fed Collagen Peptides. It contains affiliate links - if you buy through them, a commission may be earned at no extra cost to you. That relationship doesn't change how the research is presented or what the studies actually say. All research citations are attributed to their sources. All brand claims are labeled as brand-stated. Full disclosure in accordance with FTC 16 CFR Part 255.

GLP-1 Medications and Bone Loss in Women: 2.6% Hip Density Drop in 52 Weeks, What the Wegovy Label Discloses About Fractures, and What to Do While the Weight Is Still Coming Off (2026)

Last Updated: June 2026. Research citations current as of June 2026. Product offer terms are subject to change; verify at the official brand website before purchasing.

View the Current NativePath Collagen Offer - GLP-1 + Frother LP Promotion

TL;DR - Quick Answer: GLP-1 medications and bone loss in women is an active area of emerging clinical concern. The FDA-approved Wegovy prescribing information discloses that in the SELECT cardiovascular outcomes trial, hip and pelvis fractures occurred more often in female patients on Wegovy than on placebo (1% vs. 0.2%) - a finding from a population with pre-existing cardiovascular disease. A 2024 phase 2 RCT documented 2.6% hip and 2.1% lumbar spine bone density reductions within 52 weeks at the 1.0 mg semaglutide dose in a specific study population. A February 2026 study found an 11% higher fragility fracture risk in GLP-1 users in a specific diabetic population. NativePath Grass-Fed Collagen Peptides is positioned by the brand as nutritional support during significant weight loss - sourced from grass-fed South American cattle, manufactured in the USA, currently offered at 45% off with free shipping and a free frother per brand promotional materials. Speak with your licensed healthcare provider before adding any supplement to your protocol.

NativePath Collagen (2026) - Quick Verification Snapshot

• As of June 2026: NativePath Grass-Fed Collagen Peptides is a hydrolyzed bovine collagen supplement marketed by NATIVEPATH LLC, headquartered at 1395 Brickell Ave., Suite 800, Miami, FL 33131.

• Phone: 1-800-819-2993.

• Email: cs@nativepath.com. Co-founded by Dr. Chad Walding, DPT (Doctor of Physical Therapy), based in Austin, Texas.

• Single ingredient: hydrolyzed bovine collagen (Type I and Type III peptides). Sourced from grass-fed, pasture-raised cattle in South America (Brazil, Argentina, and Colombia per brand FAQ).

• Retail price: $37.99 per jar (25 servings, 10g per scoop).

• Current promotional offer: up to 45% off with free shipping and a free USB frother for qualifying orders.

• Guarantee: 365-Day "Feel Good" Guarantee from date of delivery (limited - see full terms at official website). Return shipping is the buyer's responsibility. Return Authorization required. No subscription required for this offer.

• Trademark registration status: not independently verified as registered; ® not applied.

• Note: Prices, promotional offers, and guarantee terms are subject to change; verify current details at the official NativePath website before purchasing.

NativePath Collagen (2026) Fast Facts: What Every Buyer Should Know Before Clicking Anything

• NativePath Collagen: single-ingredient hydrolyzed bovine collagen powder - Type I and Type III peptides

• Source: grass-fed, pasture-raised cattle from South America (Brazil, Argentina, Colombia per brand FAQ); manufactured in the USA

• Dose per scoop: 10 grams of hydrolyzed collagen peptides; 25 servings per standard retail jar

• Third-party tested: brand states testing for heavy metals, toxins, and microbes; no solvents used in processing

• Allergens: free from soy, gluten, dairy, GMOs; made on equipment that processes milk, eggs, fish, tree nuts, and soy

• Collagen types: Type I and Type III - the two types making up more than 90% of the body's collagen per brand materials; found in bones, skin, tendons, and connective tissue

• Dissolvability: dissolves instantly in hot or cold liquid; tasteless, odorless

• Co-founder: Dr. Chad Walding, Doctor of Physical Therapy, Austin, Texas

• Price: $37.99 retail per jar; up to 45% off per current promotional offer (verify at official site)

• Frother LP offer: current promotional bundle includes a free USB frother with qualifying orders

• Shipping: free on qualifying orders; typically ships within 24 hours; 7-10 business days expected delivery in the USA per brand FAQ

• Guarantee: 365-Day "Feel Good" Guarantee from date of delivery (limited - buyer pays return shipping; Return Authorization required; full terms at official site)

• No subscription required: this offer is structured as a one-time purchase

• Headquarters: NATIVEPATH LLC, 1395 Brickell Ave., Suite 800, Miami, FL 33131

• Support: 1-800-819-2993 | cs@nativepath.com | Live Chat 8-5 Central Time, Mon-Fri

• Wegovy prescribing information disclosure: In the SELECT cardiovascular outcomes trial (adults with pre-existing CV disease), hip and pelvis fractures were reported more often in female Wegovy patients than placebo (1% vs. 0.2%) - this is Adverse Reactions section data from FDA-reviewed prescribing information, applicable to that specific trial population; review your medication's prescribing information with your licensed healthcare provider

• Key research context: A 2024 phase 2 RCT documented 2.6% hip and 2.1% lumbar spine BMD reduction in a specific semaglutide study population within 52 weeks; a 2026 study found 11% higher fragility fracture risk in GLP-1 users in a specific older diabetic population; findings vary by study design, population, and dose

View the Current NativePath Collagen Offer - GLP-1 + Frother LP Promotion

Why You're Reading This - And What You're Actually Going to Learn

If you're on a GLP-1 medication - or you've been thinking about starting one - there's something worth knowing that your doctor probably hasn't brought up yet. Not because they're negligent. Because the research on it is only a year or two old, and the standard follow-up appointment wasn't built around it.

NativePath the caloric restriction and appetite suppression that GLP-1 medications produce may affect structural tissue too - specifically bone mineral density and lean mass. We now have randomized controlled trial data from 2024 and a prospective substudy from 2025 documenting measurable changes in both. That data is real, peer-reviewed, and worth understanding before another month goes by.

This article isn't telling you to stop your medication. That's a conversation for you and your prescriber. What this article will do is walk you through what the research actually found, explain why there's often a gap between what the science shows and what comes up at follow-up appointments, and give you an honest look at NativePath Grass-Fed Collagen Peptides - what it is, what the brand says about it, what's independently verifiable, and how to think about whether it belongs in your protocol.

Here's how this works: every brand claim is clearly marked as coming from NativePath. Every research finding is attributed to its study. You're not going to be asked to take anything on faith. Read through, decide what's relevant to your situation, and bring what matters to your next appointment.

Who this article is for: Women currently on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) who want to understand what emerging research says about bone health during rapid weight loss. Women considering starting a GLP-1 medication who want the complete picture. Women who've already decided to add collagen protein to their protocol and are evaluating NativePath specifically. If none of those describe you, this article may not be the most useful thing you read today - and that's fine.

Buyer Takeaway 1: This article separates peer-reviewed research on GLP-1 medications and bone health from what NativePath says about its product. Both categories are worth your attention. Neither is a substitute for a conversation with your doctor.

What Emerging Research Says GLP-1 Medications May Do to Your Bones - The Studies Your Doctor May Not Have Read Yet

Quick Answer: Emerging research from 2024-2025 suggests GLP-1 receptor agonist medications may be associated with bone density changes in specific populations, primarily driven by rapid weight loss rather than a confirmed direct drug effect on bone cells. The most rigorous bone-specific human RCT to date found statistically significant reductions in hip and lumbar spine bone density within 52 weeks in a specific study population. The research is active, evolving, and not settled - but it's consistent enough that leading endocrinologists are calling for musculoskeletal monitoring as a standard part of GLP-1 prescribing.

Let's start with what the research actually says - because it's more specific and more recent than most people realize. This is an evolving field, and what's described here reflects the best available human evidence as of 2025, not a decades-long consensus. That distinction matters. It's part of why many providers aren't raising it yet, and why it's worth you raising it with them.

In 2024, a randomized, double-blinded phase 2 clinical trial published in eClinicalMedicine (Hansen et al.) followed 64 adults at increased fracture risk for 52 weeks on once-weekly semaglutide 1.0 mg versus placebo. That dose - 1.0 mg - is the glycemic-management dose of semaglutide, lower than the 2.4 mg weekly dose used for chronic weight management in the Wegovy formulation. Different doses and different GLP-1 medications may carry different skeletal profiles; the research picture for higher doses used specifically for weight loss is still being built. The findings were the most rigorous bone-specific data on GLP-1 therapy available to date. At the end of one year, the semaglutide group showed a 2.6% reduction in hip bone mineral density and a 2.1% reduction at the lumbar spine compared to the placebo group - with increased bone resorption markers and no compensatory increase in bone formation. In plain terms: the bone was breaking down faster, and the signals that would normally trigger rebuilding weren't keeping pace.

That trial focused on semaglutide. A separate analysis - the SURMOUNT-1 DXA substudy by Look et al., published in Diabetes, Obesity and Metabolism in 2025 - tracked the body composition effects of tirzepatide over 72 weeks. The headline finding: total lean mass declined by 10.9% over that period. In standard DXA methodology, lean mass primarily measures non-fat soft tissue - predominantly muscle - rather than bone mineral content, which is reported separately. So this finding and the bone density finding from Hansen et al. are measuring different things: together they paint a picture of rapid weight loss affecting multiple structural compartments simultaneously, not just fat.

A large retrospective cohort study from Weill Cornell Medical College - examining 255 patients (92% women, mean age 64) with DXA scans before and after starting semaglutide or tirzepatide - found that GLP-1 receptor agonist use was associated with greater annualized total hip bone loss in patients without diabetes, while patients with diabetes showed bone loss more comparable to non-users. As a retrospective cohort design, this study documents association rather than causation; prospective data in this specific population is still developing. The finding is clinically meaningful: for the many women using these medications specifically for weight management rather than diabetes treatment, the bone consequences appear more pronounced.

A 2024 clinical trial published in JAMA Network Open divided weight-loss patients into three groups: exercise-only, GLP-1 medication-only, and GLP-1 medication combined with exercise. The results were instructive. GLP-1 medication alone was associated with bone density decline at the hip and spine. Exercise alone preserved bone density while still producing weight loss. GLP-1 medication paired with exercise produced the greatest total weight loss while also preserving bone density. That's not a finding suggesting GLP-1s should be avoided - it's a finding suggesting that musculoskeletal support, including resistance training, isn't optional for women on these medications.

It's also worth noting that the research picture on GLP-1s and bone is still evolving. Some observational data and animal model research has suggested GLP-1 receptor agonists may have direct bone-protective signaling effects that could modulate long-term fracture risk. The 2024-2025 RCT and cohort data represent the most rigorous current human evidence, but this is an active research area, and the picture will continue to develop. Reasonable endocrinologists and orthopedic specialists interpret the current findings with appropriate uncertainty - and with appropriate urgency about building a protection plan from the start of GLP-1 therapy.

Buyer Takeaway 2: The 2024 Hansen et al. The RCT in eClinicalMedicine and the 2025 SURMOUNT-1 DXA substudy represent the most rigorous current human evidence on how GLP-1 medications may affect bone and lean mass in specific study populations. These findings suggest that rapid weight loss on these medications may come with a structural cost that standard follow-up appointments aren't always designed to catch. Speak with your licensed healthcare provider about whether bone health monitoring is appropriate for your specific situation and medication.

Read: NativePath Collagen Peptides Product Information Updated as Consumer Interest in Collagen Supplement Options Grows in 2026

Why the Bone Changes Don't Show Up on the Scale - And Why That Makes the 52-Week Window So Important

Here's what the scale won't tell you: not what's coming off - only how much. That distinction is the entire issue.

When you're losing weight quickly - whether through GLP-1 therapy, caloric restriction, or a combination - your body pulls energy and raw materials from whatever it can access most efficiently. In an ideal scenario, that's primarily stored fat. But the body doesn't operate in an ideal scenario when the caloric deficit is steep. It also draws on lean tissue: muscle fibers, bone matrix, and the collagen-based connective tissue that gives your skin its elasticity, your joints their cushion, and your bones their structural framework.

NativePath's co-founder, Dr. Chad Walding (Doctor of Physical Therapy), describes this dynamic in the brand's educational content. According to Dr. Walding, as published on the NativePath brand website: "When women dramatically cut their calories - for any reason - they're often cutting protein with it. And protein, specifically the amino acids that build collagen, is what your body uses to maintain bone, muscle, skin, and connective tissue. If the raw materials stop coming in, the body starts drawing down what it already has."

That's a brand-attributed perspective - Dr. Walding is speaking as NativePath's co-founder and spokesperson, not as an independent researcher. But the underlying biochemistry he's describing aligns with what the research literature documents about caloric restriction and lean tissue loss. The amino acids that comprise collagen - primarily glycine, proline, and hydroxyproline - are used extensively in bone matrix, cartilage, tendons, and skin. When dietary protein intake drops during rapid weight loss, the body's ability to maintain these tissues can be compromised.

The visible consequence many women notice first is what the brand describes as a "hollow, drawn look" - the sudden deflation of facial volume that can make the face look gaunt rather than thinner after significant rapid weight loss. That's the collagen-depletion effect at the surface level. The harder-to-see consequences - lower bone density, reduced grip strength, joint discomfort, hair thinning, nail brittleness - tend to develop more quietly and show up later.

They also tend to show up in a DEXA scan rather than a mirror, which is why most women don't connect the symptoms to the weight loss until something more dramatic - a fracture from a minor fall, for example - forces the issue.

Buyer Takeaway 3: The scale doesn't distinguish between fat loss and lean tissue loss. The structural consequences of rapid weight loss - including bone density reduction and collagen depletion - develop quietly over months and frequently go undetected until a DXA scan or a significant injury prompts a closer look.

View the Current NativePath Collagen Offer - GLP-1 + Frother LP Promotion

What Does Collagen Peptide Supplementation Research Actually Show?

Before getting to what NativePath specifically offers, it's worth understanding what the peer-reviewed research actually says about collagen peptide supplementation - because this is a YMYL category, and the distinction between ingredient-level research and finished-product claims matters considerably.

The most rigorous bone-specific human clinical trial on collagen peptide supplementation is König et al., published in Nutrients (PMC) in January 2018. It was a 12-month, randomized, placebo-controlled, double-blinded study enrolling 131 postmenopausal women with reduced bone mineral density (DXA T-scores of -1 or lower at either the femoral neck or lumbar spine). Participants received either 5 grams of specific collagen peptides (SCP) per day or a matched maltodextrin placebo. The primary endpoint was BMD change at the femoral neck and lumbar spine after 12 months.

Results in the 102 women who completed the study showed that BMD at the spine and femoral neck increased significantly in the SCP group compared to the control group. Bone formation markers (P1NP) increased in the SCP group while bone resorption markers (CTX-1) decreased - suggesting a shift toward net bone formation rather than net bone loss. The researchers concluded that combined oral administration of bovine collagen peptides showed promise as a nutritional approach for supporting bone health in postmenopausal women with osteopenia.

A few things are important to understand about that study. First, it used specific collagen peptides at 5 grams per day - a dose lower than the 10-20 grams that some clinical research on muscle and joint outcomes has employed. Second, it was conducted in postmenopausal women with already-reduced bone density - not in women actively undergoing rapid weight loss or GLP-1 therapy. The research doesn't tell us what happens when collagen peptides are used specifically as a supplement during GLP-1 therapy. That's an important gap.

What the research does tell us is that hydrolyzed collagen peptide supplementation has shown statistically significant, measurable effects on bone density markers in a well-designed human clinical trial - specifically in the population (postmenopausal women) most likely to be experiencing bone loss. Whether those effects translate directly to women in the GLP-1-therapy-plus-weight-loss context requires additional research that hasn't been published yet.

The NCCIH (National Center for Complementary and Integrative Health) and systematic review bodies generally characterize the evidence on collagen peptides as preliminary but promising for specific outcomes including skin elasticity and joint comfort, with bone density outcomes needing additional large-scale replication. That's the honest summary: the König et al. 2018 RCT is well-designed and positive - and it's not the final word. It's one strong data point in an evolving picture, which is why a provider conversation matters before acting on it.

Important: Research findings cited in this section pertain to hydrolyzed collagen peptides as an ingredient category - not specifically to NativePath's finished product. These statements have not been evaluated by the Food and Drug Administration. NativePath Grass-Fed Collagen Peptides is not intended to diagnose, treat, cure, or prevent any disease.

Buyer Takeaway 4: A 12-month RCT published in Nutrients (König et al., 2018) found that specific collagen peptides at 5g/day produced statistically significant improvements in bone mineral density markers in 131 postmenopausal women with reduced BMD. This is ingredient-level research, not finished-product testing. The applicability to women on GLP-1 therapy specifically is not yet studied. Speak with your healthcare provider before adding any supplement during medical weight loss therapy.

Does NativePath Collagen Work?

Quick Answer: NativePath Grass-Fed Collagen Peptides is a dietary supplement, not a drug. It doesn't treat or prevent bone loss. What it provides is hydrolyzed bovine collagen - Type I and Type III peptides - that NativePath positions as nutritional support during significant weight loss, per brand materials. The most relevant human clinical research on this ingredient category (König et al., 2018, Nutrients) showed statistically significant improvements in bone density markers in 131 postmenopausal women with reduced BMD over 12 months. That's ingredient-level evidence - not a claim about this specific product. Individual results vary. These statements have not been evaluated by the FDA.

Short answer: NativePath Collagen is a food supplement, not a medication. It hasn't been FDA-approved to treat or prevent anything - no dietary supplement is. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

What it actually is - according to the brand - is a clean, single-ingredient hydrolyzed bovine collagen powder that delivers Type I and Type III collagen peptides in a form the body can use. NativePath positions it as nutritional support for structural health during periods of increased demand: significant weight loss, aging-related collagen decline, or both. The brand cites approximately 1.5% annual collagen depletion starting in the 30s, per brand materials.

Individual results vary. Customer results published on the brand's website have not been independently verified. The brand's Terms and Conditions acknowledge that results described in testimonials and marketing materials represent experiences that may not be typical and may be composites of real customer feedback rather than specific named individuals' documented outcomes.

What's verifiable about NativePath Collagen Peptides is its composition and sourcing: a single ingredient (hydrolyzed bovine collagen), grass-fed, pasture-raised South American cattle, manufactured in the USA, and third-party tested for purity. Those are the facts a buyer can confirm. Whether those facts translate into the structural support the brand describes - and over what timeframe - depends on individual factors including diet, activity level, baseline health status, and the reason for weight loss, all of which a healthcare provider is better positioned to assess than any supplement article.

Buyer Takeaway 5: NativePath Collagen is a dietary supplement, not a drug. It's not FDA-approved and it doesn't treat or cure any disease. The brand positions it as nutritional support for structural health during weight loss. Individual results vary and are not independently verified. Confirm with your licensed healthcare provider whether it's appropriate for your specific situation before starting.

About the "Hidden Trade-Off" Language in This Article

The phrase "hidden trade-off" in this article refers specifically to a topic that may not be emphasized in standard weight-loss follow-up visits - not a suggestion that doctors, pharmaceutical companies, or regulators are concealing information. The word "hidden" reflects a gap in routine clinical conversation, not bad faith by any party. The peer-reviewed research documenting bone mineral density losses during GLP-1 therapy is real and recent (2024-2025). The standard weight-loss follow-up appointment typically focuses on glycemic markers, blood pressure, cholesterol, and overall weight change - not DXA-confirmed bone density or lean mass composition. That's not negligence; it reflects the primary clinical purpose of the visit.

The "trade-off" framing is an accurate editorial description of what the published evidence shows: meaningful weight loss on one side of the scale, measurable bone and lean tissue loss on the other. The hidden aspect is that the structural losses don't produce symptoms most women would immediately connect to their weight loss - until a fall, a fracture, or a DEXA scan requested for another reason creates the connection retroactively.

NativePath's brand educational content uses similar framing. The brand's spokesperson, Dr. Walding, describes seeing women "in their 50s with the bone density of women in their 70s" - attributed to him on the brand's published website. That's a brand-stated clinical observation, not a peer-reviewed finding. It's included here to give you the brand's perspective alongside the independent research, clearly labeled as each.

Buyer Takeaway 6: The "hidden trade-off" language accurately reflects a gap between what GLP-1 clinical research is documenting about bone loss and lean mass reduction (2024-2025 peer-reviewed studies) and what's typically discussed at standard weight-loss follow-up appointments. It's not a fabricated concern - and it's not a reason to stop taking a medication your doctor prescribed. It's a reason to ask your doctor about a musculoskeletal protection plan.

What to Look for in a Collagen Supplement (The Sourcing and Quality Checklist)

Walk into any grocery store or search Amazon and you'll find dozens of collagen products at wildly different price points making nearly identical claims. Most aren't worth buying - not because of fraud, but because they cut corners on the things that actually matter. Here are the five variables that separate a meaningful collagen supplement from an overpriced placebo - and how NativePath addresses each of them, based on brand-published disclosures.

• Source quality: Collagen is extracted from animal connective tissue - typically bovine hides. Cattle raised in conventional feedlot conditions, fed grain, and treated with growth hormones and antibiotics produce biochemically different collagen than cattle raised on pasture in grass-fed systems. The difference matters because the amino acid profile of collagen is influenced by the animal's diet and environment. NativePath sources from grass-fed, pasture-raised cattle in South America (Brazil, Argentina, and Colombia per brand FAQ). That's a verifiable sourcing claim - the brand discloses the geographic origin of its supply chain, which most collagen brands don't do.

• Collagen type specificity: There are 28 identified types of collagen in the human body, but approximately 90% of the body's total collagen is Type I and Type III, according to the brand's published materials - a figure consistent with what structural biology resources describe about collagen composition in skin, bone, tendon, and connective tissue. NativePath contains specifically Type I and Type III peptides. Products labeled "multi-collagen" that blend types from multiple animal sources (chicken, fish, bovine, egg) may contain collagen types (Type II, Type V, Type X) with less robust human clinical evidence behind them. NativePath's positioning is single-source, Type I and III only.

• Hydrolyzation: Collagen protein in its native form is a large triple-helix molecule that the digestive system can't efficiently absorb intact. Hydrolyzation is the process of breaking those molecules down into shorter peptide chains - the result is what's called "hydrolyzed collagen peptides" or "collagen hydrolysate." NativePath's collagen is hydrolyzed to a specific molecular weight the brand describes as optimized for absorption. This is the same processing method used in the König et al. 2018 study and in most published clinical research on collagen peptide supplementation.

• Label cleanliness: A single-ingredient collagen supplement should contain one ingredient: hydrolyzed bovine collagen. NativePath's ingredient list is exactly that - one ingredient. No sweeteners, no flavors, no gums, no fillers, no binding agents. It's free from gluten, soy, dairy, and GMOs. The brand also discloses a shared equipment advisory: made on equipment that also processes milk, eggs, fish, tree nuts, and soy, which is standard disclosure practice for individuals with specific allergen concerns.

• Third-party purity testing: The brand states that every batch is tested by third parties for heavy metals, toxins, and microbes, and that no solvents are used in processing. This is especially relevant for a supplement sourced from bovine connective tissue, where heavy-metal testing provides meaningful assurance of purity. The brand doesn't publish individual lot test results on a public certificates-of-analysis page in the way some supplement brands do - buyers who want COA documentation should contact NativePath customer support directly.

• Dose: NativePath delivers 10 grams of collagen peptides per scoop. The König et al. 2018 bone density RCT used 5 grams per day. Brand materials reference research using 10-20 grams per day for muscle and joint outcomes. A 10g single-scoop dose sits at the middle of the range used in clinical research, which is appropriate positioning for a once-daily supplementation protocol.

Buyer Takeaway 7: Five quality variables distinguish meaningful collagen supplements from filler: source quality (grass-fed sourced), type specificity (Type I and III), hydrolyzation, ingredient cleanliness (single ingredient), and third-party purity testing. NativePath addresses all five by brand disclosure. Confirm any specific claims with the brand directly, including COA availability, before purchase.

Also Read: Expert Analysis on the Top Grass-Fed Collagen for Skin and Joint

What Does NativePath Collagen Contain? - Ingredient Breakdown

NativePath Grass-Fed Collagen Peptides contains exactly one ingredient: hydrolyzed bovine collagen. That's the complete Supplement Facts panel. There are no secondary ingredients, no proprietary blends, no undisclosed additives.

Bovine collagen is derived from the hides of cattle. The hydrolysis process cleaves the native collagen triple helix into shorter peptide chains, producing a powder that dissolves rapidly in both hot and cold liquids. The resulting peptides are predominantly glycine, proline, and hydroxyproline - the three amino acids that form the core of collagen's structural backbone and that have been the subject of the most clinical research on collagen supplementation outcomes.

At 10 grams per scoop (one serving), each serving provides 9 grams of protein per the brand's published nutrition facts. The product is tasteless and odorless, and the brand describes it as dissolving "clump-free with stirring" in 8-12 oz of any liquid. The brand notes that, unlike many protein powders, NativePath Collagen doesn't contain any form of sweetener, which means it won't affect blood sugar - a relevant consideration for women using GLP-1 medications for metabolic management.

For women concerned about allergen exposure, the product contains no added milk, shellfish, tree nuts, wheat, peanuts, or soy - but it is made on equipment that processes all of these, which should be factored in by anyone with a documented sensitivity to these allergens.

Collagen peptides are generally well-tolerated by most adults. There are no well-characterized interactions between plain collagen peptides and common GLP-1 medications in the published literature as of this article's preparation date. Nonetheless, if you're taking any prescription medication and considering adding a supplement, the conversation should happen with your prescribing provider before you start - not after.

Buyer Takeaway 8: NativePath Collagen Peptides contains a single ingredient - hydrolyzed bovine collagen - providing 10g collagen (9g protein) per scoop. No sweeteners, no fillers, no proprietary blend. Tasteless, odorless, dissolvable in any liquid. Made on shared equipment with common allergens. Consult your healthcare provider before adding any supplement if you're on prescription medication.

Who Is Dr. Chad Walding? - Understanding the Brand's Credential Claim

You'll notice that most of NativePath's educational content - including the bone loss and collagen materials - comes through Dr. Chad Walding. Here's who he is and what that means for how you should read his statements.

The credential - Doctor of Physical Therapy - refers to a clinical doctoral degree in physical therapy, typically awarded after three years of post-undergraduate professional education focused on musculoskeletal assessment, rehabilitation, and movement science. DPT practitioners are licensed clinicians with substantial training in bone, joint, and connective tissue health - the exact systems that GLP-1-related lean mass loss affects most directly. Dr. Walding is described by the brand as being based in Austin, Texas.

It's important to understand what this means for evaluating NativePath's content. Dr. Walding is speaking in his capacity as NativePath's co-founder and as a credentialed physical therapist - not as a researcher who has published independent peer-reviewed studies on collagen peptide supplementation. His comments, as published on the NativePath website, represent the brand's clinical perspective and educational positioning. They are brand-attributed content, not independent clinical research findings. Both his credential and that distinction are worth holding in mind as you read the brand's materials.

NativePath's official site also references endorsements from other healthcare practitioners who speak favorably of collagen supplementation in general. These should be evaluated as brand-attributed testimonials, not independent endorsements. Individual professionals' experiences and opinions about supplements vary, and none of these statements have been independently audited or verified by this publication.

Buyer Takeaway 9: Dr. Chad Walding's credential (Doctor of Physical Therapy) is a legitimate clinical doctorate in musculoskeletal health - the systems most relevant to GLP-1-related bone and lean tissue loss. His statements on NativePath's website are brand-attributed educational content from the brand's co-founder, not independently published research. Evaluate them accordingly.

You're Losing Weight Right Now: What Should You Actually Be Doing About Your Bones?

You're probably not here because you want a research paper. You're here because you're losing weight, you're on a medication your doctor prescribed, and something in the back of your mind is asking whether there's a trade-off nobody's told you about.

The Washington Post put it well in March 2026: "The miracle of rapid weight loss has always come with fine print." Until recently, that fine print was mostly a list of digestive complaints. The emerging research suggests the fine print may now include something more structural.

Here's what the evidence says you should actually be doing about it.

If you're on a GLP-1 receptor agonist - semaglutide, tirzepatide, or another GLP-1-class medication - and you're experiencing meaningful weight loss, here's what the published evidence and clinical consensus suggest a responsible musculoskeletal protection plan looks like. None of these recommendations come from NativePath. They come from the peer-reviewed literature, including the researchers who conducted the bone density studies cited earlier in this article.

• Get a baseline DXA scan. If you don't know where your bone density stands today, you have no baseline against which to measure changes. The 2024-2025 research showing bone loss on GLP-1 therapy identified those losses by comparing pre-treatment and post-treatment DXA measurements. You need both measurements to know what's happening. Ask your prescribing provider whether a baseline DXA is appropriate for your situation.

• Prioritize resistance training. The JAMA Network Open 2024 trial found that GLP-1 medication combined with exercise produced the greatest weight loss while preserving bone density - while GLP-1 medication alone produced bone loss. The bone-preservation signal from resistance exercise is well-established in the general literature: mechanical loading stimulates osteoblast activity, which maintains and can rebuild bone density. At minimum, two to three sessions per week of weight-bearing or resistance exercise is what most sports medicine and orthopedic specialists would recommend for a patient on GLP-1 therapy.

• Optimize protein intake. GLP-1 medications significantly reduce appetite and caloric intake. That reduction tends to fall disproportionately on protein, because protein-rich foods (meat, eggs, dairy, legumes) are satiating and dense, meaning smaller meals contain less of them. Aim for adequate protein distribution across meals - around 25-30 grams per meal - even when your appetite is suppressed. Adequate protein intake supports both muscle preservation and collagen synthesis.

• Discuss calcium and vitamin D with your provider. Both are directly involved in bone mineralization. Many women on calorie-restricted diets are vitamin D deficient, and calcium intake often drops with overall caloric intake. Your provider can check levels and advise supplementation if appropriate.

• Consider collagen peptides as part of your protein strategy. This is where NativePath's offering becomes relevant to the conversation. The König et al. 2018 RCT showed that 5 grams of specific collagen peptides per day led to measurable improvements in BMD over 12 months in postmenopausal women with reduced bone density. Whether similar outcomes apply during active GLP-1 therapy hasn't been directly studied. But collagen peptides are a recognized dietary protein source - providing glycine, proline, and hydroxyproline in bioavailable form - and adding 10 grams of high-quality hydrolyzed collagen daily is a low-risk nutritional strategy for a population that's already reducing total protein intake. Discuss this with your provider before starting.

Buyer Takeaway 10: The published evidence points toward a four-part musculoskeletal protection strategy during GLP-1 therapy: baseline DXA measurement, resistance training at least twice weekly, adequate protein at every meal, and appropriate calcium/vitamin D. Collagen peptide supplementation is a reasonable discussion item to raise with your provider as part of overall protein strategy - not as a replacement for any of the above.

Explore NativePath Grass-Fed Collagen Peptides - See Current Pricing and Offer Details

What NativePath's Marketing Actually Means - Decoded for Buyers Who Want the Truth

NativePath's promotional materials use several phrases that deserve clarity - not because they're improper, but because understanding what they mean precisely will help you make a better-informed decision.

• "Supports bone mineral density" - This is a DSHEA (Dietary Supplement Health and Education Act) structure/function claim. It means the brand is describing the product's role in supporting a normal physiological process - in this case, bone mineralization. It doesn't mean the product treats osteoporosis, prevents fractures, or has been FDA-approved for bone-density indication. The clinical research cited in NativePath's content (König et al. 2018) is ingredient-level research on specific collagen peptides, not a study of NativePath's specific formulation.

• "45% off" promotional pricing - This refers to a brand-stated promotional discount from a brand-stated reference price of $37.99 per jar. Comparison pricing reflects the brand's own reference pricing and may not represent the price you'd find through all retail channels. The promotional discount percentage is subject to change; verify the current offer at the official NativePath website before purchasing. Prices shown at checkout may vary by quantity and may include additional promotional items (such as the free USB frother in the current GLP-1 + Frother LP offer).

• "365-Day Feel Good Guarantee" - This is a brand-stated limited warranty, not a "full" warranty under the Magnuson-Moss Warranty Act. A "limited" warranty means there are conditions and exclusions. Specifically per NativePath's published Refund Policy: only items from your most recent order are eligible; return shipping is the buyer's responsibility; a Return Authorization is required; original shipping costs are non-refundable; and multiple opened units of the same product flavor may only result in a refund for one opened unit. The 365-day window starts from the date of delivery, not from the date of purchase. Review the full Refund Policy at the official NativePath website before purchasing.

• "Free shipping" - Brand-stated for qualifying orders through the promotional offer page. Standard shipping terms apply to orders outside this promotional context; verify at checkout.

• "9,000+ five-star reviews" (as stated on the brand website's promotional bar) - This is a brand-reported review count. Customer ratings and testimonials are brand-reported, not independently audited by this publication. Individual experiences vary. This publication cannot verify the sourcing, screening, or authenticity of third-party consumer reviews - and encourages buyers to consult reviews critically, weighing reviewer-specific context against their own situation. Per FTC guidelines (16 CFR Part 465, effective October 21, 2024), consumers are also encouraged to evaluate whether reviews reflect verified purchases.

• "Doctor-founded" - Dr. Chad Walding, DPT, is co-founder of NativePath, per brand materials. DPT is a Doctor of Physical Therapy - a licensed clinical practitioner, not a medical doctor (MD or DO). His credential is genuine; his perspective on musculoskeletal health is that of a trained physical therapy clinician and supplement company co-founder, not an independent researcher.

Buyer Takeaway 11: Reading supplement marketing accurately means knowing the regulatory framework behind common phrases. "Supports bone mineral density" is a DSHEA structure/function claim, not an FDA drug indication. "365-Day Guarantee" is a limited warranty with specific exclusions. Review counts are brand-reported. Understanding these distinctions is the difference between making an informed decision and being surprised after purchase.

Does Ozempic Affect Bone Density? Does Wegovy Increase Fracture Risk? Here's What the Evidence and the FDA Label Actually Say

These are two of the most searched questions in this category right now - and they deserve direct answers, not hedged non-answers.

• On Ozempic (semaglutide 0.5-2.0 mg, primarily for Type 2 diabetes management): A February 2026 study published in the Journal of Clinical Endocrinology & Metabolism (Kasher Meron et al.) examined fragility fracture rates in adults aged 65 and older with Type 2 diabetes who started GLP-1 medications versus those taking other diabetes medications. The finding: an 11% higher risk of fragility fractures in the GLP-1 group. The lead author noted that both older age and Type 2 diabetes are independent fracture risk factors - meaning the at-risk population is facing compounding risks, not a single-source problem. As a retrospective study, this documents association rather than causation, and results in younger, non-diabetic weight-loss patients may differ.

• On Wegovy (semaglutide 2.4 mg, approved for chronic weight management): The FDA-approved prescribing information for Wegovy discloses that in the SELECT cardiovascular outcomes trial - a large study conducted in adults with established cardiovascular disease - hip and pelvis fractures were reported more often in female patients on Wegovy than in those on placebo: 1% (24/2,448) versus 0.2% (5/2,424). This disclosure appears in the Adverse Reactions section of Wegovy's FDA-reviewed prescribing information. The SELECT trial enrolled a specific population - adults with pre-existing cardiovascular disease - so this finding applies directly to that population. That context matters. What also matters is that this is the data Novo Nordisk submitted to the FDA and the FDA chose to include in the prescribing information - meaning regulators considered it relevant for healthcare providers and patients to know.

• What this means for you: Neither finding means these medications are unsafe or that benefits don't outweigh risks for appropriately screened patients. The experts who published and commented on this research were consistent on that point. What they do mean is that bone health monitoring - a baseline DXA scan, adequate protein and calcium intake, resistance training - is a necessary part of responsible GLP-1 therapy, not an optional extra. The researchers who published the 2026 fracture study explicitly recommended that bone density screening happen before starting GLP-1 therapy in older patients - not after a fracture forces the issue.

Buyer Takeaway 21: Wegovy's FDA-reviewed prescribing information discloses that in the SELECT cardiovascular outcomes trial, hip and pelvis fractures occurred more often in female patients on Wegovy than placebo (1% vs. 0.2%) - data from a population with pre-existing cardiovascular disease. A February 2026 peer-reviewed study (Kasher Meron et al.) found an 11% higher fragility fracture risk in GLP-1 users aged 65+ with Type 2 diabetes versus those on other diabetes medications - a retrospective study showing association, not proven causation. Both findings are from citable published sources. Neither means these medications should be avoided. Both mean musculoskeletal monitoring during GLP-1 therapy is appropriate for at-risk populations. Speak with your licensed healthcare provider about bone health monitoring before and during any GLP-1 treatment.

The Bone Loss Window Is Asymmetric - And That's the Part Nobody Tells You

Here's the urgency lever that the clinical articles acknowledge but none of the consumer-facing content explains clearly enough.

Bone loss associated with rapid weight loss often does not fully reverse even after weight stabilizes. That's not a worst-case scenario - it's a documented pattern in the weight-loss literature. Unlike fat tissue, which is metabolically flexible and responsive to caloric changes in both directions, bone mineral density lost during rapid weight loss requires active, sustained intervention to rebuild - and even with intervention, recovery is neither guaranteed nor complete.

The implication is important: there's an asymmetry to the trade-off. You can choose to slow your weight loss later. You can adjust your medication with your provider. But the bone changes that happen in the first six to twelve months of significant, rapid weight loss may be the hardest ones to reverse. Which is why the researchers publishing this data are consistently making the same recommendation: start the protection plan on day one, not after a fracture or a concerning DEXA result prompts action.

This is what "before another month goes by" means in the context of this topic. Not manufactured urgency - calendar urgency. Every week of adequate collagen protein, resistance training, and calcium intake is a week your bones have the building materials they need. Every week without it is a week they're potentially drawing down on reserves instead.

NativePath positions its Grass-Fed Collagen Peptides as nutritional support for exactly this context, per brand materials - providing the Type I and III collagen amino acids (glycine, proline, hydroxyproline) that bone matrix formation depends on. Whether adding it to your protocol makes sense for your specific situation is a provider conversation. What isn't a conversation is the biology: the bone matrix requires those amino acids, and rapid weight loss tends to reduce their dietary supply.

Buyer Takeaway 22: Bone density lost during rapid weight loss often does not fully reverse after weight stabilizes - the literature documents this pattern consistently. This asymmetry is why starting a musculoskeletal protection plan early matters more than starting it after a concerning result. Speak with your licensed healthcare provider about whether a DXA baseline, resistance training protocol, protein optimization, and collagen peptide supplementation are appropriate additions to your GLP-1 therapy plan.

The GLP-1 and Collagen Gap: What the Research Doesn't Know Yet

An honest account of this topic has to include what the science doesn't yet know - because this is a fast-moving area where research is trailing the adoption curve.

Millions of women have started GLP-1 receptor agonist therapy in the past three years. The published RCT data on bone density consequences is only beginning to emerge. The Hansen et al. 2024 trial included 64 participants - meaningful as a phase 2 RCT, but small by the standards of definitive phase 3 evidence. The Weill Cornell retrospective cohort was larger (255 GLP-1RA subjects) but retrospective, meaning causation is harder to establish than in a prospective RCT. Long-term fracture data on women who've been on semaglutide or tirzepatide for three or more years doesn't yet exist in published form.

On the collagen side: no published RCT has specifically examined whether collagen peptide supplementation mitigates GLP-1-associated bone loss. That's the precise research question that would most directly answer what women on GLP-1 therapy want to know - and it hasn't been done. The König et al. 2018 data is from a different population (postmenopausal women not on GLP-1 therapy) using a different dose (5g vs. NativePath's 10g). Extrapolation from one study population to another has limits.

It's also worth noting that the GLP-1 bone story isn't uniformly negative in the research. A separate study on liraglutide - an earlier GLP-1 medication - found that it actually increased bone formation by 16% and reduced total bone mineral content loss compared to a control group during a weight maintenance phase after caloric restriction. The research picture is more nuanced than any single headline: some GLP-1 agents, at some doses, in some populations, may have bone-protective signaling effects. The 2024 semaglutide phase 2 RCT and the Weill Cornell cohort data are the most rigorous current evidence showing bone loss - but reasonable endocrinologists interpret even those findings with appropriate uncertainty about generalizability.

What we have is a plausible biological hypothesis (collagen peptide supplementation provides the amino acid substrates that bone matrix formation depends on, which may be relevant when those substrates are being depleted by rapid weight loss) supported by a strong positive RCT in a related population - and no direct evidence yet in the GLP-1 therapy population specifically.

That's not a reason to dismiss the hypothesis. It's a reason to discuss it with a knowledgeable provider, pursue a baseline DXA if appropriate, and make decisions with realistic expectations rather than promises.

Buyer Takeaway 12: No published RCT has specifically studied collagen peptide supplementation as a countermeasure to GLP-1-associated bone loss. The König et al. 2018 data applies to a different (though related) population. The hypothesis is biologically plausible and supported by ingredient-level evidence. The GLP-1-specific confirmation hasn't been published yet. Ask your provider for guidance given your specific clinical situation.

NativePath Collagen vs. Other Collagen Options - Category Comparison

Here's the honest comparison you won't usually find in a supplement article: how NativePath actually stacks up against the category it occupies, and what that category comparison means for you.

The category broadly divides into three segments: single-ingredient hydrolyzed bovine collagen products (NativePath's category), "multi-collagen" blends combining multiple animal sources and collagen types, and marine collagen products derived from fish skin. Each has a different research basis.

Single-ingredient hydrolyzed bovine collagen products - the category NativePath occupies - have a more extensive human clinical research base for the outcomes most relevant here. The König et al. 2018 RCT used bovine collagen peptides. The FORTIBONE and VERISOL proprietary collagen peptides used in some bone-specific and skin-specific collagen products are also bovine-derived. Marine collagen is typically Type I only and carries some preliminary research on skin elasticity, but far less bone-specific evidence. Multi-collagen blends add Types II, V, and X from additional sources; the clinical evidence for those collagen types in the outcomes relevant to this article (bone and lean tissue preservation during weight loss) is substantially thinner than for Type I and III bovine collagen.

Within the single-ingredient bovine collagen category, the differentiators are sourcing (grass-fed vs. conventional - NativePath is grass-fed), dose (NativePath's 10g/scoop sits at or above most competitors' per-serving doses), label cleanliness (NativePath: one ingredient), and purity verification (NativePath: third-party tested, no solvents). NativePath also distinguishes itself through its educational content and the clinical framing that Dr. Walding provides - which matters to buyers who want to understand the mechanism behind the supplement, not just take it on faith.

That said: collagen peptides are not a proprietary active pharmaceutical ingredient. The quality of hydrolyzed bovine collagen from different reputable brands at similar sourcing standards can be functionally comparable. The price, sourcing transparency, purity documentation, and brand's clinical education are the differentiators that matter most in this category. NativePath addresses all four of these factors by what's publicly verifiable - though buyers who want independent confirmation of specific claims (such as batch-level COA documentation) should request that directly from the brand.

Buyer Takeaway 13: Single-ingredient hydrolyzed bovine collagen (NativePath's category) has a stronger human clinical evidence base for bone and connective tissue outcomes than multi-collagen blends or marine collagen. Within its category, NativePath differentiates on grass-fed sourcing, a clean one-ingredient label, third-party purity testing, and transparent clinical education. Functional quality differences between reputable single-ingredient bovine collagen brands at similar sourcing standards may be modest - sourcing transparency and purity verification are the most important variables.

Current NativePath Offer: What You Get and What You're Agreeing To

The current GLP-1 + Frother LP promotional offer from NativePath includes: NativePath Grass-Fed Collagen Peptides (quantity and pricing per current offer page), up to 45% off the brand's stated $37.99 retail price per jar, free shipping on qualifying orders (per brand promotional materials; verify at checkout), and a free USB frother. Pricing and offer terms are subject to change at any time without notice; verify current pricing and included items at the official NativePath website before completing your purchase.

Pricing at checkout reflects the discount applied to the brand's reference price. Tax components are calculated separately at checkout and will vary by location. Shipping is free for qualifying orders under this promotional offer. The EU Omnibus Directive requires that promotional prices reference the lowest price from the prior 30 days; EU buyers should verify compliance with current pricing directly with the brand. Buyers in all geographies should confirm the final total at checkout before completing the purchase, as prices advertised in promotional materials may differ from the final checkout total due to applicable taxes and any offer-specific conditions.

The 365-Day "Feel Good" Guarantee is a limited warranty. Key limitations to understand before purchasing: only items from your most recent order are eligible for return; return shipping is your responsibility; a Return Authorization must be obtained before sending anything back (call 1-800-819-2993, Monday-Friday, 8AM-5PM Central Time); original shipping costs are non-refundable; for multiple opened units of the same product, only one opened unit qualifies for a full refund; refunds are processed to the original form of payment within 5 business days of passing inspection at the warehouse. Full terms available at the official NativePath return policy page.

There is no subscription or auto-renewal component to this offer as currently structured. This is a one-time purchase offer. No recurring charges will be assessed by the brand for this product unless you separately enroll in a subscription program offered elsewhere on the brand's website.

Buyer Takeaway 14: The current NativePath offer includes 45% off, free shipping, and a free frother on qualifying orders. The 365-Day Guarantee is a limited guarantee with conditions - review the full terms at the official NativePath website before purchasing. Return shipping is the buyer's responsibility, and a Return Authorization is required. No subscription or auto-renewal on this offer. Confirm final pricing, included items, and all terms at the official website before purchase.

View the Current NativePath Collagen Offer - GLP-1 + Frother LP Promotion

Disclosure: If you buy through this link, a commission may be earned at no extra cost to you.

How to Use NativePath Collagen - Brand's Recommended Protocol

Per NativePath's published brand materials, the recommended use protocol for Grass-Fed Collagen Peptides is straightforward. Add one scoop (10 grams) to 8-12 oz of any hot or cold beverage - coffee, tea, water, a smoothie, or any other liquid you prefer. Stir one time. The brand describes the dissolution as clump-free and instant. No blender required, no refrigeration required, no preparation window needed. The product is tasteless and odorless, meaning it genuinely doesn't alter the flavor profile of whatever you add it to.

For women who want to take two scoops daily (20 grams) - the higher end of the dose range that appears in some research on muscle and joint outcomes - NativePath's value-size bag product offers 56 servings per bag specifically to support that higher dosing protocol without running out mid-month. For this article's context (first-time buyers evaluating NativePath for GLP-1 bone loss support), the standard 10g once-daily protocol aligned with the König et al. 2018 research dose range is the appropriate starting point to discuss with your provider.

The brand recommends starting with at least a 90-day supply, noting that structural outcomes from collagen supplementation - consistent with clinical research - tend to develop over months of consistent use rather than days or weeks. Individual response timelines vary. Discontinuing and restarting creates gaps in the consistency that the research suggests matters for observable outcomes.

Buyer Takeaway 15: NativePath Collagen is positioned by the brand for once-daily use: one scoop (10g) in 8-12 oz of any liquid, stirred once. Dissolves instantly, tasteless, odorless. The brand recommends a minimum 90-day consistent use window to assess individual response - consistent with how structural collagen outcomes are measured in clinical research. Discuss appropriate dosing with your healthcare provider before starting.

Is NativePath Collagen Legit? - Verification Checklist

Quick Answer: NativePath Grass-Fed Collagen Peptides is a verifiable product from a verifiable company - NATIVEPATH LLC, 1395 Brickell Ave., Suite 800, Miami, FL 33131, phone 1-800-819-2993, cs@nativepath.com. Single ingredient (hydrolyzed bovine collagen), sourced from grass-fed South American cattle, manufactured in the USA, third-party tested per brand materials. Current promotional offer: up to 45% off plus free shipping and a free frother, per brand promotional materials. 365-Day limited guarantee with conditions - review all terms at nativepath.com before purchasing.

Yes - NativePath is a real company with a real product and real contact information. NATIVEPATH LLC is headquartered at a verifiable address in Miami. The sourcing claims (grass-fed South American cattle, manufactured in the USA) are consistent with what the brand's publicly accessible FAQ and checkout pages disclose. The co-founder's credentials (Dr. Chad Walding, DPT) are consistent with what the brand presents across its website and educational content. The 365-day guarantee is detailed on the official Return Policy page, including specific terms and limitations. There's no mystery about what this product is or where it comes from.

• What you can verify before purchasing: the brand's address and contact details (above), the single-ingredient label claim (brand publishes the Supplement Facts on product pages), the sourcing disclosure (grass-fed South American cattle, manufactured USA - in brand FAQ), the guarantee terms in detail (official Return Policy page), the current promotional pricing (promotional offer page - verify before checkout), and the brand's co-founder identity (Dr. Chad Walding, DPT, verifiable through brand's About/bio content).

• What you can't independently verify without direct contact: individual batch COAs (certificates of analysis from third-party testing), specific country of origin for any given batch (brand states Brazil, Argentina, Colombia; specific batch-level origin not published publicly), and the brand-stated review count of 9,000+ five-star reviews (brand-reported; not independently audited by this publication).

If any of those unverifiable items are decision-relevant for you, contact NativePath customer support directly at 1-800-819-2993 or cs@nativepath.com before purchasing. The brand offers live chat Monday through Friday, 8AM-5PM Central Time.

Buyer Takeaway 16: NativePath Collagen is a verifiable product from a verifiable company with full contact disclosure. Sourcing, ingredient, guarantee terms, and co-founder credentials are publicly documented. Batch-level COA documentation and exact country-of-origin per order are not publicly published and should be requested from support if relevant to your decision. Contact: 1-800-819-2993 | cs@nativepath.com.

What the GLP-1 Bone Loss Research Means for Women Over 40 Specifically

The research on GLP-1 therapy and bone loss is generating particular clinical attention in the context of women over 40 - and specifically women in perimenopause and menopause - because this population already faces a well-documented accelerated rate of bone density loss driven by estrogen decline. Adding GLP-1-associated bone resorption to that baseline trajectory creates a compounding effect that's not yet fully characterized in long-term outcome data but that's biologically logical to worry about.

The Weill Cornell cohort study (255 GLP-1RA subjects, 92% women, mean age 64) found that greater annualized hip bone loss was concentrated in patients without diabetes - exactly the demographic of postmenopausal women using GLP-1s purely for weight management. That's not an incidental finding. It's a signal that the population most likely to seek GLP-1 therapy for cosmetic and metabolic weight goals (rather than diabetes management) may be the population bearing the greatest skeletal cost.

The NativePath brand's lander content specifically targets women over 40 on GLP-1 therapy, framing the bone loss trade-off in terms that this population will recognize: the wrist fracture from a minor fall, the DEXA scan revealing unexpectedly poor bone density, the deflated facial appearance that doesn't match the improved scale reading. These aren't invented fears - they're the clinical presentations that the 2024-2025 research is now documenting with DXA and biomarker data.

For women in this demographic, the discussion with a healthcare provider should include: current bone density baseline (DXA if not recently done), adequacy of protein and calcium intake on a GLP-1-suppressed appetite, and whether a structured supplementation protocol - including collagen peptides as part of an overall protein strategy - is appropriate to layer in alongside resistance exercise and adequate vitamin D.

Buyer Takeaway 17: Women over 40 on GLP-1 therapy face a compounding bone-loss risk: estrogen-related density reduction plus GLP-1-associated bone resorption. The Weill Cornell 2025 cohort data found the greatest GLP-1-associated bone loss in patients without diabetes - the precise demographic of postmenopausal women on GLP-1 therapy for weight management. This demographic should specifically discuss DXA baseline, protein adequacy, and musculoskeletal protection strategies with their healthcare provider.

The 5 Most Important Questions to Ask Your Doctor About GLP-1 Therapy and Bone Health

If you're currently on or considering a GLP-1 receptor agonist, here are the five questions that the 2024-2025 research suggests are most important to raise at your next appointment - regardless of whether you're interested in NativePath or any other supplement.

• 1. "Should I get a baseline DXA scan?" The bone loss data from the 2024-2025 studies required pre-treatment and post-treatment measurements to detect change. Without a baseline, you won't know whether your density has shifted or by how much. Ask your provider whether a baseline scan makes sense given your age, menopausal status, and fracture history. It's a 15-minute test that gives you a before-photo for your skeleton.

• 2. "Am I actually eating enough protein?" GLP-1 medications reduce appetite significantly - and protein tends to be the first thing to drop when portion sizes shrink, because protein-rich foods are dense and filling. The irony is that protein is exactly what your bones and muscles need most during rapid weight loss. Your provider or a registered dietitian can help you figure out a realistic target given your appetite situation.

• 3. "Are my calcium and vitamin D levels where they need to be?" Both are directly involved in bone mineralization, and both tend to drop during caloric restriction simply because you're eating less overall. A blood test can check your vitamin D level specifically; your provider can advise on supplementation if it's low. This is one of the most straightforward things you can actually do something about.

• 4. "What kind of exercise actually helps here?" The 2024 JAMA Network Open trial found that GLP-1 medication combined with exercise preserved bone density, while GLP-1 medication alone was associated with bone density decline. Resistance training specifically - weight-bearing, strength-focused movement - sends the mechanical signal that tells bone to maintain its density. Your provider or a physical therapist can help you build a protocol that fits where you are right now, not where you think you should be.

• 5. "Is collagen protein worth adding to what I'm already doing?" Frame it as a protein strategy question, not a supplement question - because at the biochemical level, that's exactly what it is. Hydrolyzed collagen peptides deliver glycine, proline, and hydroxyproline: the amino acids that bone matrix and connective tissue depend on. NativePath positions its Grass-Fed Collagen Peptides as nutritional support in this category, per brand materials. Whether adding it makes sense for your specific situation - given your medication list, dietary baseline, and health history - is a question your provider is best positioned to answer.

Buyer Takeaway 18: The five most useful questions for your GLP-1 follow-up appointment: (1) Do I need a baseline DXA? (2) Am I meeting protein targets on a suppressed appetite? (3) Are my calcium and vitamin D levels adequate? (4) What resistance training protocol makes sense for me? (5) Is collagen peptide supplementation appropriate as part of my protein strategy? These questions reflect what the 2024-2025 research says matters - not supplement marketing.

Frequently Asked Questions About GLP-1 Medications and NativePath Collagen

What do GLP-1 medications do to bone density?

GLP-1 receptor agonists produce significant weight loss, and that rapid weight loss is associated with measurable bone mineral density reduction in multiple peer-reviewed studies. The most rigorous bone-specific RCT to date - Hansen et al. (eClinicalMedicine, 2024) - found that 52 weeks of once-weekly semaglutide at 1.0 mg reduced hip bone mineral density by 2.6% and lumbar spine BMD by 2.1% compared to placebo in 64 adults with elevated fracture risk. Note that this trial used semaglutide at 1.0 mg - the glycemic-management dose - rather than the 2.4 mg dose used for weight management (Wegovy); outcomes at different doses and for different GLP-1 medications may vary. A separate 2025 cohort study from Weill Cornell found greater annualized hip bone loss in GLP-1RA users without diabetes compared to matched non-users. These findings are from peer-reviewed research and represent the current best evidence on GLP-1 medications and bone. They don't establish that GLP-1s should be avoided - they establish that a musculoskeletal protection plan is a necessary component of responsible GLP-1 therapy. Consult your prescribing provider for guidance specific to your situation.

Does collagen supplementation help with bone loss during weight loss?

The most relevant published human clinical trial is König et al. (Nutrients, 2018) - a 12-month, randomized, double-blinded, placebo-controlled study of 131 postmenopausal women with reduced bone density. Participants taking 5 grams of specific collagen peptides daily showed statistically significant improvements in bone mineral density at the femoral neck and lumbar spine compared to placebo, along with favorable changes in bone formation and resorption markers. This is ingredient-level research on bovine collagen peptides, not on NativePath's specific product, and it was conducted in postmenopausal women not specifically on GLP-1 therapy. Whether the same outcomes apply during active GLP-1 treatment hasn't been directly studied. The biological hypothesis is plausible - collagen peptides supply the amino acids (glycine, proline, hydroxyproline) that bone matrix formation requires, which may be particularly useful when dietary protein is being restricted. Discuss with your healthcare provider whether collagen supplementation is appropriate for your situation before starting.

Is NativePath Collagen FDA-approved?

No. NativePath Grass-Fed Collagen Peptides is a dietary supplement regulated under DSHEA (Dietary Supplement Health and Education Act). Dietary supplements are not FDA-approved for the treatment, prevention, or cure of any disease or condition. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. NativePath Collagen is not a drug and has not undergone the FDA new drug application or pre-market approval process required for pharmaceutical products. It's a food-based nutritional supplement that the brand positions to support normal physiological processes within the framework of DSHEA-permitted structure/function claims.

How long does it take for NativePath Collagen to work?

According to the brand's published materials, NativePath recommends a minimum 90-day consistent use window to assess individual response. This framing is consistent with how outcomes were measured in the most relevant clinical research: the König et al. 2018 bone density RCT ran for 12 months; skin and joint studies on collagen peptides have typically measured outcomes at 8-12 weeks for early signals and 24 weeks or longer for structural changes. Individual response timelines vary based on baseline status, diet, activity level, dosing consistency, and individual biochemistry. The brand also notes that many buyers report noticing changes in skin, nails, and hair within a few weeks - outcomes that reflect more rapidly renewing tissue types compared to bone. No timeline guarantees are made by this publication, and individual results will vary.

What is the NativePath 365-Day Guarantee, and does it cover opened products?

The NativePath 365-Day "Feel Good" Guarantee is a limited guarantee with conditions, offering a refund on eligible products from your most recent order within 365 days of delivery. Key terms: sealed, unopened products qualify for a full refund. For opened products, if you have multiple opened units of the same product or flavor, only one opened unit qualifies for a full refund. Return shipping is the buyer's responsibility. A Return Authorization must be obtained by calling 1-800-819-2993 (Monday-Friday, 8AM-5PM Central Time) before returning anything. Original shipping costs are non-refundable. This warranty is designated "limited" under the Magnuson-Moss Warranty Act, meaning it has conditions and exclusions. The full terms are published on NativePath's official Return Policy page - review them before purchasing.

Is NativePath Collagen safe to take with GLP-1 medications?

Plain hydrolyzed bovine collagen peptides are a food protein and are not known to have pharmacological interactions with GLP-1 receptor agonists in the published literature as of this article's preparation. However, this publication cannot provide medical advice, and any supplement taken alongside a prescription medication should be discussed with your prescribing provider before you start. Your provider has access to your complete medication list, health history, and clinical context that this article doesn't. Dietary supplement safety for your specific situation is a clinical question, not a marketing question.

Who is NativePath Collagen best suited for?

NativePath's brand positioning - per its GLP-1 + Frother LP lander - targets women experiencing significant weight loss who are concerned about the structural consequences: bone density, muscle and collagen preservation, skin elasticity, hair and nail health, and joint comfort during weight-loss-related body composition changes. Per the brand's general marketing, the product is also positioned for women over 40 navigating age-related collagen decline and for individuals seeking a clean, single-ingredient protein source that's easy to add to an existing daily routine. Whether it's appropriate for your individual situation is a discussion for you and your healthcare provider - particularly if you're on prescription medication or managing a diagnosed condition.

Does NativePath Collagen contain any allergens?

NativePath Grass-Fed Collagen Peptides contains no added milk, shellfish, tree nuts, wheat, peanuts, or soy. It is free from gluten, dairy, and GMOs. However, the product is made on equipment that also processes milk, eggs, fish, tree nuts, and soy. Individuals with documented allergen sensitivities to any of those substances should factor that shared-equipment advisory into their decision and may wish to contact NativePath directly (1-800-819-2993 or cs@nativepath.com) for additional manufacturing detail before purchasing.

What makes NativePath different from other collagen powders?

NativePath Grass-Fed Collagen differentiates itself through four publicly verifiable characteristics: grass-fed, pasture-raised South American sourcing (Brazil, Argentina, Colombia per brand FAQ); a single-ingredient clean label (hydrolyzed bovine collagen only - no fillers, sweeteners, or additives); third-party purity testing (heavy metals, toxins, microbes; no solvents); and manufacturing in the USA. The brand also differentiates through its educational content - framed by Dr. Chad Walding, DPT, NativePath's co-founder - which addresses the clinical mechanisms behind structural collagen loss during weight loss in a more substantive way than most collagen brands attempt. These differentiators are brand-stated characteristics; buyers who want documentation of third-party testing results for specific batches should request COA information from NativePath customer support.

How much does NativePath Collagen cost?

NativePath Grass-Fed Collagen Peptides has a stated retail price of $37.99 per jar (25 servings, 10g per scoop). The current GLP-1 + Frother LP promotional offer includes up to 45% off with free shipping and a free USB frother on qualifying orders, which per the brand's lander materials can bring the per-jar cost down to approximately $21 per jar at the higher-quantity tier. All pricing is brand-stated, is subject to change without notice, and should be verified at the official NativePath website before completing any purchase. Taxes are calculated separately at checkout. The "before" price of $37.99 is the brand's stated reference price and may not represent the price available through all retail channels.

Can NativePath Collagen be taken by men?

Yes. NativePath Grass-Fed Collagen Peptides is a single-ingredient bovine collagen powder with no sex-specific formulation components. While the brand's GLP-1 and bone loss educational content focuses on women over 40 - reflecting the demographic most affected by GLP-1-associated bone loss in the research literature - the product itself is not gender-specific. Men on GLP-1 therapy or men concerned about collagen and connective tissue support have no ingredient-level reason not to consider this product; individual clinical appropriateness remains a provider conversation regardless of gender.

What happens if I don't get enough collagen during rapid weight loss?

Per Dr. Chad Walding's educational content on the NativePath brand website - attributed to him as the brand's co-founder and Doctor of Physical Therapy spokesperson - when dietary protein intake drops during significant caloric restriction, the body may draw on existing collagen-based tissue reserves for amino acids, particularly the glycine and proline needed to maintain structural functions. The brand-stated consequences include lower bone density, reduced muscle mass and grip strength, thinner-looking and less elastic skin, hair shedding, weaker nails, and joint discomfort. These observations from brand content are consistent with what structural biology and the rapid-weight-loss research literature describe about lean tissue loss during aggressive caloric restriction. They represent brand-attributed clinical perspective - not a peer-reviewed published finding about collagen deficiency in GLP-1 patients specifically. Consult your healthcare provider for guidance on optimal protein intake and structural support during your weight loss process.

Is there a free trial for NativePath Collagen?

No free trial is documented in the brand's current offer materials for the GLP-1 + Frother LP promotion. The current offer is a one-time purchase at a promotional discount (up to 45% off) with free shipping and a free frother. The 365-Day "Feel Good" Guarantee functions as the risk-reduction mechanism - allowing returns of eligible products within 365 days from delivery subject to the limitations described above (buyer pays return shipping; Return Authorization required; only one opened unit of the same product per most recent order qualifies for full refund). There is no recurring billing, auto-renewal, or subscription associated with this offer as currently structured.

Where is NativePath Collagen manufactured?

NativePath Grass-Fed Collagen Peptides is manufactured in the USA, per the brand's FAQ and Amazon product listing. The collagen itself is sourced from grass-fed, pasture-raised cattle in South America - specifically Brazil, Argentina, and Colombia per the brand's published FAQ. "Manufactured in the USA" refers to the processing, hydrolyzation, quality testing, and packaging - not the geographic origin of the bovine source material. Both sourcing facts are brand-stated and publicly disclosed.

Does Ozempic cause bone loss?

Emerging research suggests that GLP-1 receptor agonists, including semaglutide (sold as Ozempic and Wegovy), may be associated with bone density changes in specific populations, primarily through the mechanism of rapid weight loss rather than a proven direct drug effect on bone tissue. A February 2026 study in the Journal of Clinical Endocrinology & Metabolism found an 11% higher fragility fracture risk in older adults with Type 2 diabetes using GLP-1 medications versus those using other diabetes medications - though this was a retrospective study documenting association, not proven causation. A 2024 phase 2 RCT (Hansen et al., eClinicalMedicine) found a 2.6% reduction in hip bone mineral density within 52 weeks in a specific study population using semaglutide at 1.0 mg weekly. The research picture is active and evolving - some studies in different populations have found neutral or even positive bone effects. If you're taking Ozempic and concerned about bone health, speak with your licensed healthcare provider about whether a baseline DXA scan and musculoskeletal protection plan are appropriate for your situation.

Does Wegovy increase fracture risk?

The FDA-reviewed prescribing information for Wegovy (semaglutide 2.4 mg) discloses that in the SELECT cardiovascular outcomes trial - which enrolled adults with established cardiovascular disease - hip and pelvis fractures were reported more often in female patients on Wegovy than in those on placebo: 1% (24 of 2,448 patients) versus 0.2% (5 of 2,424 patients). This is Adverse Reactions section data from the prescribing information, applicable to the SELECT trial population specifically. The SELECT trial participants had pre-existing cardiovascular disease, which is an important population qualifier. Additionally, research presented at the American Academy of Orthopaedic Surgeons' 2026 annual meeting raised questions about bone and connective tissue effects in GLP-1 users more broadly. These findings don't establish that Wegovy should not be used - the cardiovascular, metabolic, and weight-management benefits are substantial and well-documented. They establish that bone health monitoring is an appropriate part of Wegovy therapy, particularly for postmenopausal women and older adults. Discuss your specific fracture risk with your licensed healthcare provider before and during any GLP-1 treatment.

What is the "52-week window" for GLP-1 bone changes?

The "52-week window" refers to the timeframe of the Hansen et al. (eClinicalMedicine, 2024) phase 2 RCT - the most rigorous bone-specific human clinical trial on semaglutide published to date. That study found statistically significant reductions in hip bone mineral density (2.6%) and lumbar spine bone mineral density (2.1%) after 52 weeks of once-weekly semaglutide at 1.0 mg in adults with elevated fracture risk. The significance of the 52-week timeframe is that meaningful bone density changes were documentable within one year - a window most women on GLP-1 therapy are currently inside, or have already passed. This is why the research consistently recommends starting a musculoskeletal protection plan at the beginning of GLP-1 therapy rather than after a concerning result surfaces. The 52-week window isn't a deadline - it's a reminder that structural changes can accumulate quietly over months without producing obvious symptoms until something more dramatic, like a fracture, forces attention to them.

Does NativePath ship internationally?

NativePath's return policy and shipping information focus on US delivery timelines (7-10 business days, ships within 24 hours). International shipping availability and terms should be confirmed directly with NativePath customer support at 1-800-819-2993 or cs@nativepath.com before purchasing. EU and international buyers should also verify that the 365-Day Guarantee is enforceable in their jurisdiction and should confirm pricing compliance with applicable local consumer protection regulations before purchasing.

What to Do Next - A Straightforward Action Plan

If you've read this far, you already know more about GLP-1 medications and bone health than most patients who've been on these drugs for a year. That knowledge is the point. Use it.

If you're in the first two groups: the most important next step is a conversation with your prescribing provider - specifically about a DXA baseline, about whether you're hitting protein targets on a suppressed appetite, and about whether a formal musculoskeletal protection plan makes sense to layer in. Your provider may or may not have seen the 2024-2025 research yet. Bringing the specific citations (Hansen et al., eClinicalMedicine 2024; Look et al., Diabetes, Obesity and Metabolism 2025) gives them something concrete to work with in your clinical context.

If you've already had that conversation and you're ready to add collagen supplementation: NativePath is the kind of product that checks the right boxes - single ingredient, grass-fed South American cattle, Type I and III peptides, properly hydrolyzed, third-party tested per brand materials, made in the USA. The 365-Day limited guarantee (conditions apply - review them before you buy) gives you a genuine window to assess your own response. The current GLP-1 + Frother LP offer brings the per-jar cost down significantly from the brand's stated retail price, per promotional materials.

Verify current pricing and terms at the official NativePath brand website before purchasing - that's the authoritative source for what the offer actually includes right now.

Visit nativepath.com - Official NativePath Brand Website

If you have questions before purchasing, contact NativePath directly: 1-800-819-2993 | cs@nativepath.com | Live Chat 8-5 Central Time, Mon-Fri.

Buyer Takeaway 19: The most important action before purchasing any supplement during medical weight loss therapy is a conversation with your prescribing provider. Bring the specific peer-reviewed citations from this article to that conversation. Then make your supplementation decision with your provider's input and your verified understanding of what the product is, what it isn't, and what the guarantee covers.

Final Verdict: Is NativePath Collagen Worth Considering for Women on GLP-1 Therapy?

Here's the bottom line, stated as plainly as possible: if your provider thinks collagen supplementation makes sense for your situation, NativePath is a well-made product that checks every box the category has. It's not going to rebuild bone on its own. It's not a substitute for exercise or your medication. But as part of a real plan - one that includes resistance training, adequate protein, a DXA baseline, and a provider who's actually paying attention to your bone health - it's a legitimate addition worth discussing.

The bone loss data on GLP-1 medications is real. It's peer-reviewed. And the researchers who published it aren't writing editorials saying "maybe worry about this someday" - they're calling for DXA baselines, resistance training, and protein optimization to become standard of care from day one of GLP-1 therapy. That recommendation isn't on most patients' radar yet because it's only started appearing in the literature in 2024 and 2025. That gap is real, and it matters.

The collagen peptide data - König et al. 2018, 131 postmenopausal women, 12-month RCT - is genuine and positive. It doesn't prove what NativePath specifically will do for you in your GLP-1 context. But the biological rationale is sound, the ingredient evidence is real, and adding a clean, single-ingredient 10g hydrolyzed collagen to your daily protein intake is a discussion-worthy nutritional option for appropriate adults, subject to your licensed healthcare provider's guidance.

Based on brand-published materials, NativePath appears to address the major quality factors buyers typically evaluate in this category: grass-fed South American sourcing, Type I and III peptides only, hydrolyzation, a single-ingredient label, brand-stated third-party testing, and US manufacturing. The 365-Day limited guarantee (conditions apply - review them) makes a genuine 90-day assessment financially low-risk. The current GLP-1 + Frother LP promotional pricing takes a meaningful chunk off the per-jar cost.

What it can't do: replace your medication, reverse bone loss on its own, substitute for resistance training, or make up for protein deficiency that's affecting multiple systems simultaneously. It's a piece of the puzzle - a good piece, well-made and well-positioned for this exact situation. But the puzzle needs all its pieces to work.

Buyer Takeaway 20: NativePath Collagen is a quality single-ingredient collagen supplement positioned for structural support during rapid weight loss. It meets all five sourcing and formulation quality criteria. The 365-Day limited guarantee is genuine. The current offer provides meaningful savings. It's worth considering as part of a broader musculoskeletal protection plan during GLP-1 therapy - after a provider conversation and with realistic expectations about what a dietary supplement can and cannot do.

The structural changes the research documents happen quietly over months. The protection plan that preserves what you're building doesn't require waiting for a wake-up call. That's the whole point of having this information before the DEXA scan tells you something you'd rather have caught earlier.

Get NativePath Collagen With Free Frother and Free Shipping - Verify Current Availability

Contact Information

• Company: NativePath

• Email: cs@nativepath.com.

• Phone Support: 1-800-819-2993

• Live Chat: 8-5 Central Time, Mon-Fri.

Also Read: NativePath CoQ10 Complex Complete 2026 Overview

Disclaimers

• Affiliate Disclosure. This article contains affiliate links. A commission may be earned on qualifying purchases made through links in this content, at no additional cost to the reader. Affiliate relationships do not influence editorial content or the evaluation of products. Disclosure is provided in accordance with FTC 16 CFR Part 255. This content is promotional in nature and is intended for consumer education regarding a commercially available product.

• FDA Disclaimer. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information in this article is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. Always speak with a qualified healthcare provider before starting any new supplement, especially if you have a medical condition, are pregnant or nursing, or are taking prescription medication.

• Individual Results Disclaimer. Customer results referenced in brand-attributed content in this article have not been independently verified by this publication. Individual results vary. Testimonials and case descriptions - including any narrative examples attributed to named or unnamed individuals in the brand's educational content - represent experiences that may be consistent with real customer feedback and may not be typical. Outcomes you experience may differ materially from those described. FTC 16 CFR Part 255: this publication discloses the existence of brand testimonials and encourages readers to evaluate them critically and in the context of their individual circumstances. Per FTC 16 CFR Part 465 (effective October 21, 2024): all brand-reported customer ratings and review counts referenced in this article are brand-attributed data and have not been independently audited for authenticity, sourcing, or verification of purchase status.

• Material Limitations of This Review. This review is based exclusively on publicly available materials, including the official NativePath website, the brand's published Terms and Conditions, Refund Policy, and FAQ, publicly accessible research citations, and general category-level guidance on dietary supplement evaluation. This publication has not received compensated product samples for testing, has not interviewed NativePath personnel, has not been granted access to internal product specifications beyond what is publicly published, and has not conducted laboratory or field performance testing of NativePath Grass-Fed Collagen Peptides. Claims described in this article as "according to the brand," "brand-stated," "per brand materials," or similar attribution language reflect what the brand has publicly stated and have not been independently substantiated by this publication. Buyers are encouraged to verify any claim that materially affects their purchase decision by contacting NativePath directly at 1-800-819-2993 or cs@nativepath.com.

• Third-Party Consumer Feedback Platforms. This article references the existence of third-party consumer feedback platforms and brand-reported review counts in general category terms only. This publication does not endorse, vouch for, audit, or accept responsibility for the accuracy, completeness, or fairness of customer reviews posted on any third-party platform, including general-purpose review sites, social media platforms, and online discussion forums. Buyers consulting third-party reviews are encouraged to evaluate them critically, look for verified-purchase indicators where available, and weigh reviewer-specific context against their own situation.

• Forward-Looking Statements and Article Accuracy. This article reflects information available as of June 2026 and was prepared using reasonable care to be accurate and useful at the time of publication. Product specifications, pricing, promotional offers, shipping policies, warranty terms, return policies, contact information, and customer feedback data may change after publication without notice. Statements describing expected buyer outcomes, performance expectations, or category trends are educational forward-looking observations, not guarantees. No representation is made that the information will remain accurate in the future, and no warranty of merchantability, fitness for a particular purpose, or non-infringement is provided in connection with the editorial content of this article. Readers should rely on the official NativePath website at nativepath.com as the authoritative source for current product information prior to any purchase decision.

• Reasonable Consumer Standard. This article is written for a general adult consumer audience and intends statements to be interpreted as a reasonable consumer would interpret them in context. Where a statement could otherwise be read as a brand-substantiated fact, attribution language such as "according to the brand," "brand-stated," "brand-reported," or "per the official Terms" identifies it as a brand claim that has not been independently verified by this publication. Promotional positioning and headline marketing phrases appearing on the brand's website - including, without limitation, "365-Day Feel Good Guarantee," "Stock Up and Save," and "45% off" promotional discount framing - are explicitly identified in this article as brand-stated marketing language and are not represented as independently verified performance guarantees or independently ranked designations by this publication.

• California Proposition 65 Notice. WARNING: This product is sold to consumers in California and may contain chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm. For more information: www.P65Warnings

Phone: 1 (800) 819-2993 | Email: cs@nativepath.com

SOURCE: NativePath

Source: NativePath